Why Bausch Health Stock Jumped 24% Today

Bausch Health Companies Inc. rose 24% after regular trading ended to $7.80 after reporting stronger third-quarter results and raising its full-year revenue outlook. Stronger sales and earnings show recent business strength, while the higher forecast signals management expects revenue to keep growing.

What Bausch Health Companies Inc. Does

Bausch Health makes and sells medicines for digestive, liver, brain, skin, and other conditions. It also holds a controlling interest, or majority stake, in Bausch + Lomb, an eye-care products company. Its broad range of businesses brings sales from several areas of health care.

Bausch Health Third-Quarter Earnings

Adjusted earnings per share, which leaves out costs the company treats as unusual, were $1.77. Revenue reached $2.94 billion, and profit after expenses and taxes was $436 million. Adjusted earnings per share rose 53% from a year earlier, showing stronger results than the same quarter before.

Bausch Health Fiscal 2026 Revenue Outlook

The company raised its full-year revenue forecast to $10.98B – $11.18B, above analyst expectations. A higher forecast gives investors a better view of expected sales, but future results still need to support it.

Bausch Health Draws Heavier Trading

Trading totaled about 7.9 million shares, about four times the normal pace. That heavier activity shows the response involved more trading than usual after the report.

Quick Financial Overview

Bausch Health is profitable and a mid-cap, meaning it sits in the middle range of public-company sizes. Its stock market value is $2.92B. It held $1.82B in cash and cash equivalents, meaning cash the company can spend, as of June 30, 2026.

Bausch Health Prior-Quarter Financials

Before the newly reported quarter, its June-quarter snapshot showed $2.85B in revenue and net income of $258.0M, or profit after expenses and taxes. Those earlier results show Bausch was already generating sales and profit. That history gives holders a base for judging whether the newer strength continues.

Bausch Health Stock Clears Its Monthly High

Bausch Health shares had gained 19.31% over the past month before moving above their earlier monthly high after the close. The stock is now beyond its recent range, but the chart alone cannot show whether business growth will last. For Bausch Health, the last daily move this large was sixty-three sessions ago; a session is one trading day.

Bausch Health Share Repurchase Plan

Bausch Health authorized share repurchases, meaning it can buy and cancel its own shares. The company says the plan is meant to offset shares added through employee awards. The authorization does not require the company to make any purchases.

Conclusion

Repurchases may begin on November 3, 2026, making that the next dated company event. Actual buying would show follow-through, while no purchases would leave the authorization unused. The next quarterly results, whose date is not provided, will show whether sales and earnings can keep growing.

Start Your Trial Now!